Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
|Articles|July 1, 1999
The American Journal of Managed Care
- July 1999
- Volume 5
- Issue 7
Payor Cost Savings with Endometrial Ablation Therapy
Advertisement
Articles in this issue
over 27 years ago
Hospital Expenditures and Utilization: The Impact of HMOsover 27 years ago
The Food and Drug Administration and Atrial Defibrillation Devicesover 27 years ago
Benign Prostatic Hyperplasia: New Concepts for the Millenniumover 27 years ago
Breast Cancer Prevention: The Role of AntiestrogensAdvertisement
Related to this article
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.
Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5